NCT01650961

Brief Summary

The purpose of this study is to assess the effects of palonosetron on corrected QT interval duration during and after general anesthesia.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jul 2012

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2012

Completed
23 days until next milestone

First Submitted

Initial submission to the registry

July 24, 2012

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 26, 2012

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2012

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2013

Completed
Last Updated

August 7, 2013

Status Verified

August 1, 2013

Enrollment Period

5 months

First QC Date

July 24, 2012

Last Update Submit

August 6, 2013

Conditions

Outcome Measures

Primary Outcomes (1)

  • corrected QT interval (QTc interval)

    at 2, 10, 15, 30, 60, 90 minutes after induction of general anesthesia, up to 1 minute after tracheal intubation

    up to 90 minutes after induction of general anesthesia

Secondary Outcomes (4)

  • proportion of patients whose corrected QT interval (QTc interval) is more than 450 ms for male or 470 ms for female

    up to 2 hours after induction of general anesthesia

  • corrected QT interval (QTc interval) at Postanesthetic care unit

    up to 1 hour after arrival on postanesthetic care unit

  • Incidence of postoperative nausea and vomiting

    for 24 hours after surgery

  • proportion of patients who have more than 500 ms of corrected QT interval (QTc interval)

    up to 2 hours after induction of general anesthesia

Study Arms (2)

Palonosetron

EXPERIMENTAL

Intravenous administration of palonosetron 0.075 mg before the induction of general anesthesia

Drug: Palonosetron

Control

PLACEBO COMPARATOR

Intravenous administration of normal saline before the induction of general anesthesia

Drug: Normal saline

Interventions

0.075 mg IV as bolus before induction of general anesthesia

Also known as: Aloxi
Palonosetron

2 ml normal saline as bolus before induction of general anesthesia

Control

Eligibility Criteria

Age20 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Elective abdominal surgery under general anesthesia

You may not qualify if:

  • Cardiac valvular disease
  • Clinically significant arrhythmias including atrial fibrillation
  • Anti-emetics within 24 hours before surgery
  • Steroids within 1 week before surgery
  • Cancer chemotherapy or radiotherapy within 4 weeks before surgery
  • Diabetes mellitus
  • Pregnancy
  • Patients receives a QT-prolonging drug

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Seoul National University Hospital

Seoul, South Korea

Location

Related Publications (1)

  • Kim HJ, Lee HC, Jung YS, Lee J, Min JJ, Hong DM, Choi EK, Oh S, Jeon Y. Effect of palonosetron on the QTc interval in patients undergoing sevoflurane anaesthesia. Br J Anaesth. 2014 Mar;112(3):460-8. doi: 10.1093/bja/aet335. Epub 2013 Oct 14.

MeSH Terms

Interventions

PalonosetronSaline Solution

Intervention Hierarchy (Ancestors)

QuinuclidinesHeterocyclic Compounds, Bridged-RingHeterocyclic CompoundsIsoquinolinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingCrystalloid SolutionsIsotonic SolutionsSolutionsPharmaceutical Preparations

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 24, 2012

First Posted

July 26, 2012

Study Start

July 1, 2012

Primary Completion

December 1, 2012

Study Completion

February 1, 2013

Last Updated

August 7, 2013

Record last verified: 2013-08

Locations